Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors
Molecular Pharmaceutics · 05.02.2024 · 21 (2) · 735-744
DOI: 10.1021/acs.molpharmaceut.3c00886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 09.01.2024. Verfasst von Mengshi Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, People's Republic of China. Hauptthemen laut MEDLINE: Tomography, Emission-Computed, Single-Photon, Breast Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hygiene Specific Subjects of Jilin Province.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is an emerging target for cancer diagnosis. Different types of FAP inhibitor (FAPI)-based radiotracers have been developed and applied for tumor imaging. However, few FAPI tracers for single photon emission computed tomography (SPECT) imaging have been reported. SPECT imaging is less expensive and more widely distributed than positron emission tomography (PET), and thus, 99mTc-labeled FAPIs would be more available to patients in developing regions. Herein, we developed a FAPI-04-derived radiotracer, HYNIC-FAPi-04 (HFAPi), for SPECT imaging. 99mTc-HFAPi, with a radiochemical purity of >98%, was prepared using a kit formula within 30 min. The specificity of 99mTc-HFAPi for FAP was validated by a cell binding assay in vitro and SPECT/CT imaging in vivo. The binding affinity (Kd value) of 99mTc-HFAPi for human FAP and murine FAP was 4.49 and 2.07 nmol/L, respectively. SPECT/CT imaging in HT1080-hFAP tumor-bearing mice showed the specific FAP targeting ability of 99mTc-HFAPi in vivo. In U87MG tumor-bearing mice, 99mTc-HFAPi had a higher tumor uptake compared with that of HT1080-hFAP and 4T1-mFAP tumor models. Interestingly, 99mTc-HFAPi showed a relatively high uptake in some murine joints. 99mTc-HFAPi accumulated in tumor lesions with a high tumor-to-background ratio. A preliminary clinical study was also performed in breast cancer patients. Additionally, 99mTc-HFAPi exhibited an advantage over 18F-FDG in the detection of lymph node metastatic lesions in breast cancer patients, which is helpful in improving treatment strategies. In short, 99mTc-HFAPi showed excellent affinity and specificity for FAP and is a promising SPECT radiotracer for (re)staging and treatment planning of breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, People's Republic of China.
- Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- Hygiene Specific Subjects of Jilin Province
Zitieren
APA
Ma, M., Yang, G., Zhao, M., Liu, Y., Ge, X., Jia, B., & Gao, S. (2024). Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors. Molecular Pharmaceutics, 21(2), 735-744. https://doi.org/10.1021/acs.molpharmaceut.3c00886
Vancouver
Ma M, Yang G, Zhao M, Liu Y, Ge X, Jia B, et al. Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors. Molecular Pharmaceutics. 2024;21(2):735-744. doi:10.1021/acs.molpharmaceut.3c00886
BibTeX
@article{Ma2024,
author = {Ma, Mengshi and Yang, Guangjie and Zhao, Min and Liu, Yao and Ge, Xiaoguang and Jia, Bing and Gao, Shi},
title = {Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {2},
pages = {735--744},
doi = {10.1021/acs.molpharmaceut.3c00886}
}
EUVIMED